Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis by Khanna, Dinesh et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Standardization of the modified Rodnan skin score for use in clinical trials of
systemic sclerosis
Khanna, Dinesh; Furst, Daniel E; Clements, Philip J; Allanore, Yannick; Baron, Murray; Czirjak, Lazlo;
Distler, Oliver; Foeldvari, Ivan; Kuwana, Masataka; Matucci-Cerinic, Marco; Mayes, Maureen; Medsger,
Thomas; Merkel, Peter A; Pope, Janet E; Seibold, James R; Steen, Virginia; Stevens, Wendy; Denton,
Christopher P
Abstract: The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary
or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). This state-of-art
review provides a historical perspective of the development of the mRSS, summarizes the performance of
mRSS as an outcome measure, provides guidance on assessing mRSS, and makes recommendations for
incorporation of the mRSS into clinical trials.
DOI: https://doi.org/10.5301/jsrd.5000231
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-137450
Published Version
Originally published at:
Khanna, Dinesh; Furst, Daniel E; Clements, Philip J; Allanore, Yannick; Baron, Murray; Czirjak, Lazlo;
Distler, Oliver; Foeldvari, Ivan; Kuwana, Masataka; Matucci-Cerinic, Marco; Mayes, Maureen; Medsger,
Thomas; Merkel, Peter A; Pope, Janet E; Seibold, James R; Steen, Virginia; Stevens, Wendy; Denton,
Christopher P (2017). Standardization of the modified Rodnan skin score for use in clinical trials of
systemic sclerosis. Journal of scleroderma and related disorders, 2(1):11-18.
DOI: https://doi.org/10.5301/jsrd.5000231
Standardization of the modified Rodnan skin score for use in 
clinical trials of systemic sclerosis
Dinesh Khanna1, Daniel E. Furst2, Philip J. Clements2, Yannick Allanore3, Murray Baron4, 
Lazlo Czirjak5, Oliver Distler6, Ivan Foeldvari7, Masataka Kuwana8, Marco Matucci-Cerinic9, 
Maureen Mayes10, Thomas Medsger Jr11, Peter A. Merkel12, Janet E. Pope13, James R. 
Seibold14, Virginia Steen15, Wendy Stevens16, and Christopher P. Denton17 on behalf of the 
Scleroderma Clinical Trials Consortium and the World Scleroderma Foundation
Corresponding author: Dinesh Khanna, MD, MSc, Professor of Medicine, Director, University of Michigan Scleroderma Program, 
Division of Rheumatology/Dept. of Internal Medicine Suite 7C27, 300 North Ingalls Street, SPC 5422, Ann Arbor, MI 48109, 
khannad@med.umich.edu, Phone: 734.647.8173, Fax: 734.763.5761. 
CONFLICTS
Dr. Khanna has consultancy relationships with Actelion, Bayer, Bristol-Myers Squibb, ChemomAb, Corbus, Cytori, Eicos, EMD 
Serono, Genentech/Roche, Gilead, Glaxo SmithKline, MedImmune, Medac, and Sanofi-Aventis/Genzyme. He has received research 
funding from Astra-Zeneca, Bayer, Bristol-Myers Squibb, and Pfizer. This work was funded in part by the NIH/NIAMS K24 
AR06312 grant.
Dr. Furst has consultancy relationships and/or has received research funding in relationship grant/research from Amgen, BMS, NIH, 
Novartis, Pfizer, Roche/Genentech, AbbVie, Amgen, BMS, Cytori, Janssen, NIH, Novartis, Pfizer, Roche/Genentech, and UCB.
Dr. Clements has no relevant conflicts.
Dr. Allanore has consultancy relationships and/or has received research funding in relationship with the treatment of systemic sclerosis 
from Actelion, Bayer, Biogen Idec, Bristol-Myers Squibb, Genentech/Roche, Inventiva, Medac, Pfizer, Sanofi/Genzyme, Servier and 
UCB.
Dr. Baron has no relevant conflicts.
Dr. Czirjak has consultancy relationships with the treatment of systemic sclerosis from Actelion, Bayer, Genentech/Roche, Inventiva, 
Medac, and Pfizer.
Dr. Distler has/had consulting relationships from 4 D Science, Actelion, Active Biotec, Chemom AG, Bayer, BiogenIdec, BMS, 
Boehringer Ingelheim, ChemomAb, EpiPharm, espeRare foundation, Genentech/Roche, GSK, Inventiva, Lilly, medac, Mepha, 
MedImmune, Pharmacyclics, Pfizer, Sanofi, Serodapharm, and Sinoxa; and grants from Actelion, Bayer, Boehringer Ingelheim, Pfizer, 
and Sanofi. Patent licensed: mir-29 for the treatment of systemic sclerosis. Speaker fees from AbbVie, iQone Healthcare, Mepha
Dr. Foeldvari has consultancy relationships with Bayer, Roche-Genentech, Novartis, Abbive, Chugai. Speakers fee: Pfizer, Abbvie, 
and Medac
Dr. Kuwana has consultancy or speaker fees from Bayer, Boehringer Ingelheim, Chugai, Actelion, and Glaxo SmithKline, and/or has 
received research funding from Chugai, Actelion, and Bayer.
Dr. Matucci-Cerinic has active consultancies or has received grant support from Amgen, BMS, Pfizer, Bruno farma, and Actelion. 
Consultant: BMS, Actelion, Pfizer, Inventiva, Chemomab
Dr. Mayes has consultancy relationship with and/or has received research funding from Bayer, Boehringer-Ingelheim, Corbus, Cytori, 
Genentech/Roche.
Dr. Medsger has consultancy relationship with iBio.
Dr. Merkel has consultancy relationship with and/or has received research funding from Actelion, Bristol-Myers Squibb, 
ChemoCentryx, Genentech/Roche, Glaxo SmithKline, Kypha, MedImmune/AztraZeneca, PrincipoBio, Sanofi-Aventis/Genzyme.
Dr. Pope has consultancy relationship with AbbVie, Actelion, Amgen, Bayer, BMS, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, 
Roche, Sanofi, UCB.
Dr. Seibold has consultancy relationship with Anthera, Bayer, BioGen IDEC, Blade Therapeutics, Boehringer Ingelheim, Covis 
Pharma, Cytori, Eiger, EMD Serono, Milestone, Mitsubishi, Sanofi-Aventis, Teva and Xenikos. There are no speaker’s bureaus or 
stock holdings.
Dr. Steen has consultancy fees from Bristol Myers Squibb, Cytori, Bayer, Gilead, and research grant funding from CSL Behring, 
United Therapeutics and Gilead, and Clinical Trial research funding from Cytori, Roche, Boehringer Ingelheim, EMD Serono, Covis, 
and Reata
Dr. Stevens has consultancy relationship or received research funding form Actelion, GSK, Bayer and Pfizer and has received speakers 
fees from Actelion and GSK
Dr. Denton has consultancy relationships with or speaker fees from Actelion, Bristol-Myers Squibb, GlaxoSmithKline, Bayer, Sanofi-
Aventis, Boehringer Ingelheim, Genentech-Roche, and CSL Behring, and research grant funding from GlaxoSmithKline, Actelion, 
Novartis, CSL Behring.
HHS Public Access
Author manuscript
J Scleroderma Relat Disord. Author manuscript; available in PMC 2017 May 15.
Published in final edited form as:
J Scleroderma Relat Disord. 2017 ; 2(1): 11–18. doi:10.5301/jsrd.5000231.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1University of Michigan Scleroderma Program, Ann Arbor, MI, USA 2UCLA, Los Angeles, CA, 
USA 3Paris Descartes University, rheumatology A dpt, Cochin Hospital, Paris, France 
4Department of Medicine, McGill University Division of Rheumatology Jewish General Hospital, 
Montréal, Canada 5Department of Immunology and Rheumatology, University of Pécs, Hungary 
6Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland 7Hamburger Zentrum 
für Kinder und Jugendrheumatologie, Hamburg, Germany 8Department of Allergy and 
Rheumatology, Nippon Medical School Graduate School of Medicine, 2Tokyo, Japan 9Department 
of Experimental & Clinical Medicine, Division of Rheumatology AOUC, University of Florence, 
Firenze, Italy 10University of Texas McGovern Medical School, Houston, TX, USA 11University of 
Pittsburgh, Pittsburgh, PA, USA 12University of Pennsylvania, Philadelphia, PA, USA 13Deparment 
of Medicine, University of Western Ontario, London, ON, Canada 14Scleroderma Research 
Consultants LLC, Litchfield, CT, USA 15Georgetown University, Washington DC, USA 16Division of 
Rheumatology, St. Vincent’s Hospital, Melbourne, Australia 17Centre for Rheumatology, Royal 
Free and University College London Medical School, London, UK
Abstract
The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary 
or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). This state-of-
art review provides a historical perspective of the development of the mRSS, summarizes the 
performance of mRSS as an outcome measure, provides guidance on assessing mRSS, and makes 
recommendations for incorporation of the mRSS into clinical trials.
Introduction
The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a 
primary or secondary outcome measure in clinical trials of systemic sclerosis (SSc, 
scleroderma). This article gives a brief history of the development of the mRSS, outlines 
practical aspects of assessing mRSS in clinical trials, and provides recommendations for the 
use of the mRSS in Phase 2 and 3 clinical trials where change in skin thickness is the 
primary or secondary outcome measure. This document highlights the views of scleroderma 
experts and is not meant to be used as a regulatory document.
Natural history of skin involvement in SSc
SSc is subclassified into diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc) 
based on the extent of skin involvement. lcSSc is defined as skin thickening distal to the 
elbows and knees, with or without involvement of the face. dcSSc is characterized by the 
presence of skin thickening, proximal as well as distal, to the elbows and knees with or 
without involvement of the face(7). It is generally accepted that skin thickness tends to 
increase in early dcSSc and decrease in late dcSSc, although the time of peak involvement is 
typically 12–18 months after the onset of skin thickening. “Early” dcSSc is often defined as 
the period of rapidly increasing induration (“thickening”) of the skin. Although there is 
substantial individual heterogeneity, skin involvement in dcSSc may go through 3 phases: (i) 
an edematous phase that usually lasts 6–12 months; (ii) a fibrotic or indurative phase that 
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lasts from 1–4 years or longer; and (iii) an atrophic phase that lasts for rest of the patient’s 
life, although rarely patients have a recurrence of progressive skin involvement in later 
disease (Figure 1). The duration of each phase may differ in each individual patient and the 
phases often overlap each other. The course of skin thickness also differs by serum 
autoantibodies—patients with anti-RNA polymerase-III tend to have more rapid progression 
than do those with anti-Scl-70 (topoisomerase I) antibody. In lcSSc, there is little change in 
skin thickness over time except in the subset who are anti-Scl-70 positive and progress to 
dcSSc over time(8).
Skin thickness as surrogate of disease severity and mortality
Measurement of skin thickness is used as a surrogate for disease activity, severity and 
mortality in patients with dcSSc. In early dcSSc, an increase in skin thickening is generally 
associated with new or worsening internal organ involvement and increased mortality (7, 3). 
Worsening mRSS is associated with higher mortality, and both negative renal and cardiac 
outcomes (11). Internal organ involvement or worsening are particularly associated with the 
prior trajectory of skin thickening(7), and higher skin thickness progression rates are 
predictive of internal organ involvement and mortality(8, 1). In addition, patients who never 
achieved a high skin score have a lower frequency of major organ-based complications, and 
those with high skin scores that failed to improve by 3 years of disease have significantly 
higher mortality. Conversely, attenuation of peak skin score or improvement is associated 
with favorable outcomes, including better survival(11, 12). These points emphasize the 
potential benefit of including milder or early cases of SSc in clinical trials, such as designing 
studies to evaluate either a preventative (less worsening/less peak of mRSS) and/or 
improvement strategy(10, 6)
Historical perspective
Dr. Gerald Rodnan at the University of Pittsburgh theorized about, and then studied, the 
trajectory of skin thickening in the course of SSc. He noted that the skin, particularly the 
dermis, thickened initially and after some years usually thinned. He became convinced that 
an observer could, with practice, accurately estimate how thick skin is by palpating it. To 
substantiate his point, he developed a method for estimating thickness by clinical palpation 
using a 0–4 scale. He performed an experiment in which he estimated skin thickness of the 
distal forearm by skin palpation in patients with SSc and then performed a skin punch 
biopsy in that same location. He then weighed the plug of skin from the biopsy. The 
correlation between his clinical estimate of thickness and the weight of a 7-mm punch 
biopsy plug was 0.81(2). He further explored clinical palpation for estimating skin thickness 
in 26 cutaneous sites. The first full description of his methodology was published in 1982 in 
the context of a controlled study of D-penicillamine in SSc(5).
Some years later, Dr. Rodnan’s colleagues modified his method by estimating skin thickness 
using a 0–3 scale in 17 body areas. Nine of the original areas (neck [1], shoulders [2], 
breasts [2], upper back [1], lower back [1], toes [2]) were dropped because clinical 
investigators found it too difficult to come to consensus due to high inter-observer variation. 
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One of the first applications of this mRSS(11) was in a randomized clinical trial (RCT) of 
high-dose versus low-dose D-penicillamine in early dcSSc(11, 6).
During the same period when the mRSS was developed, several groups were exploring 
different ways of assessing global skin involvement in patients with SSc. For example, 
Kahaleh et. al. proposed a modification of the Rodnan technique for measuring skin 
thickness (scores ranged from 0–66)(4). Investigators at UCLA developed a skin scoring 
technique which involved assessment of skin tethering or hidebinding in 10 body areas 
(scores ranged from 0–30)(8). Another method assessed the percentage of total body surface 
area affected by scleroderma(6). However, consensus was eventually reached where the 
mRSS became the gold standard for measuring skin thickness in SSc(6).
The modified Rodnan Skin Score (mRSS) as an outcome measure
The mRSS meets the OMERACT filters of truth, discrimination, and feasibility (Figure 2), 
as detailed in Merkel et al(7). Briefly, mRSS has the following characteristics:
a. Feasible: Easy to perform with no equipment and requires little time
b. Face Validity: Captures and measures skin thickness
c. Content Validity: Covers the affected body areas in SSc
d. Construct validity: Correlates with other measures of SSc such as durometer 
and ultrasound(5, 11)
e. Criterion Validity: Reflects the gold standard of skin biopsy(1). The correlation 
between clinical estimate of thickness by Dr. Rodnan and the weight of a 7-mm 
punch biopsy plug was 0.81(2). In addition, myofibroblast and hyalinized 
collagen scores on the skin biopsy correlated with the forearm mRSS score in a 
single center study(correlation coefficients of 0.83 and 0.78(11), respectively)
f. Sensitivity to change: Analysis of multicenter clinical trials show change over 
time. For example, the mRSS was able to differentiate between treatment with 
methotrexate and placebo in early dcSSc and between cyclophosphamide and 
placebo in the dcSSc subset in the Scleroderma Lung Study-I(25). The mRSS also 
improved in the Autologous Stem Cell Transplant Study(24) and showed a trend 
towards improvement with treatment with tociluzimab(10038). In addition, the 
minimal clinically important difference of the mRSS has been established in 
dcSSc and ranges between 3.5 to 5.3 units in the D-Penicillamine study (the 
mean baseline mRSS was 21 units(10)). The minimal clinically important 
difference estimates differ by the baseline mRSS and may be lower for recent 
trials that are recruiting milder skin thickening in dcSSc(10).
Utilizing the mRSS in clinical trials and routine care of systemic sclerosis
A. Practical aspects
1 Positioning of the patient: This is an important part of assessing mRSS. Each 
area examined should be in the relaxed position so the underlying muscles are 
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relaxed to avoid falsely overestimating the area skin scores. Proper scoring 
cannot be done with patients in regular clothes. An examination gown or loose 
clothing is needed with appropriate use of sheet/drape. When evaluating the 
upper extremities, face, and anterior chest, we recommend the patient be seated 
in a relaxed position with arms by the side of the body. When evaluating the 
abdomen and lower extremities, we recommend the patient lie supine on an 
examination table or bed with the hips at 45 degrees’ flexion and feet are 
dorsiflexed.
2 Assessing skin thickness:
a. There are 2 techniques to accomplish this by palpation of the skin 
(Figure 3a).
i. Use an index finger and thumb where the skin is rolled or 
pinched gently to gauge thickness.
ii. Use two thumbs to form a fold of skin between advancing 
lateral thumb borders. This method may be easier when skin 
overlies bone such as in the fingers and on the dorsum of the 
hands.
b. It is important to understand the relative distribution of subcutaneous 
fat and underlying musculoskeletal structures in different anatomical 
areas as they may alter the examiner’s appreciation of skin thickness.
c. Skin should be scored based on how it feels and not how it looks. For 
example, shiny skin or abnormally pigmented skin does not imply 
increased thickness.
B. Global average vs. maximum score vs. most representative area of an anatomic area
There are differences in scoring mRSS in clinical practice but we recommend standardizing 
mRSS measurement in clinical trials. The 3 commonly used techniques include:
a. Maximum score: The examiner assigns a score to individual anatomic areas 
according to the most severe local involvement. For example, if the distal 
forearm has a patch considered 2 whereas the remainder of the forearm is 1, then 
would be given a score of 2 is recorded.
b. Representative area: The examiner scores individual areas with a score that is 
most representative of the area. In the example above, 1 would be the most 
representative score.
c. Global average: The examiner scores individual areas and takes average of the 
area. In the example above, 1 would be the most representative score. However, 
if the distal forearm had areas scored 2 and 3 whereas the majority of the forearm 
is 1, the average would be 2 (differs from representative area where the score 
would be 1). Some investigators prefer not to divide the scored region formally 
into subareas but prefer to provide an average score that reflects overall skin 
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thickness and accounts for the observed variation in a more flexible fashion. 
Both methods are sound and acceptable.
We propose using either the “representative area” or “global average” method (Figure 4). In 
addition, there is a theoretical disadvantage of using “maximum score” as it may limit 
sensitivity to change. Consider an area over the forearm [as an example] that remains a 3 but 
the other forearm areas improve. Using maximum score, the forearm will continue to be 
scored as 3 despite definite improvement. One point of clarification is that if an area of skin 
has 1 but no more severe thickening, then the score of 1 is given; i.e. for global average, 
maximizing applies in this situation.
3 Scoring of each individual cutaneous area (Figure 3a–3d):
a. mRSS =0 is “normal skin” where the examiner appreciates fine 
wrinkles but no skin thickness is present.
b. mRSS =1 is defined as definite but “mild” skin thickness where the 
examiner can easily make skin folds between 2 fingers; fine wrinkles 
are acceptable.
c. mRSS =2 is defined as “moderate” skin thickness with difficulty in 
making skin folds and no wrinkles.
d. mRSS =3 is defined as “severe” skin thickness with inability to make 
skin folds between 2 examining fingers.
4 The same examiner should evaluate the skin thickness throughout the trial: 
Each outcome measure inherently has measurement variability. It is 
recommended that the same assessor examine the patient for the duration of the 
trial. The inter-observer variability of the mRSS is 4.6 units (coefficient of 
variation=25%) and the intra-observer variability is 2.5 units (coefficient of 
variation= 12%)(11), with these variabilities better than that of measuring 
swollen and tender joint counts in rheumatoid arthritis, both part of the standard 
assessment in that disease(6, 7). Others have found similar results for the 
variability of the mRSS.
5 Teaching reduces variability of mRSS: The mRSS is a validated outcome in 
dcSSc but, as in rheumatoid arthritis, training assessors reduces variability. In a 
12 investigator SSc teaching course, the ICC was 0.639, an acceptable reliability. 
On repeat training 7 months later, the ICC was 0.684, essentially the same. 
These data indicate that repeated retraining over time is not necessary (at least 
over 7 months). However, inter-investigator variability was high at both training 
sessions (standard deviation: 3.5–5.3) emphasizing that the intra-person 
reproducibility of the mRSS is much higher than between examiners; 
highlighting the need to have the same investigator consistently measuring the 
same patient(7).
Additional unpublished data comes from an investigator meeting where training 
was conducted as part of a phase II clinical trial in dcSSc. Fourteen investigators 
were asked to perform mRSS on 2 subjects with dcSSc. Immediately after the 
Khanna et al. Page 6
J Scleroderma Relat Disord. Author manuscript; available in PMC 2017 May 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
completion of mRSS, each investigator viewed a video demonstration by an 
expert examining a subject exhibiting different aspects of skin scoring, followed 
by a live demonstration by an expert on 1 subject with SSc on standardization of 
mRSS in clinical trials. Then, the investigators examined the same 2 subjects 
again and recorded their mRSS. Using a linear mixed model with random effects 
for both subjects and physicians, the results indicated that the video 
demonstration led to a decrease in the investigator variability (standard deviation 
decreased from 3.7 units before training to 1.6 units after training, a decrease of 
56%), while the variability in mRSS attributable to variability among patients 
decreased less noticeably after training (2.5 units to 2.0 units after training). The 
latter is expected as the variability in mRSS captures the inherent heterogeneity 
in mRSS that exist across subjects.
6 Caveats in mRSS measurement
a. The edematous phase of dcSSc is usually associated with non-pitting 
edema of the skin. The mRSS may be difficult to assess during the 
edematous phase of SSc and mRSS has been shown to be inaccurate in 
this setting, with a correlation between an edema score on physical 
examination and edema on biopsy of 0.069–0.169(1). There is no 
agreement upon the approach for determining thickness when skin has 
edema. ‘Puffiness’ of the skin, generally fingers, is scored as 0.
b. Tethering or hidebinding is defined as strong attachment of the lower 
dermis to the underlying subcutaneous tissues, making skin movement 
difficult even in the absence of skin thickening. Although tethering can 
occur in the fibrotic phase of the disease, it is also associated with 
atrophic or “thin” skin. The mRSS does not score tethering.
c. Atrophic skin should be given a mRSS of 0, although this is 
erroneously scored as 3 due to underlying tethering.
7 Other aspects
a. Assessment in pediatric population: In healthy children, the texture 
of the skin shows age-appropriate skin thickness due to increased 
subcutaneous fat tissue compared to adults and correlates with the body 
mass index and the Tanner stage(1). In healthy children, skin is often 
appreciated as thicker due to increased subcutaneous fat. The latter is 
correlated with body mass index (BMI) and Tanner stage and decreases 
with age and sexual maturation. mRSS is not yet validated in juvenile 
SSc but there are ongoing international efforts to accomplish this. 
Therefore, the mRSS assessment should be performed in specialized 
pediatric scleroderma centers and should be corrected for BMI and 
Tanner stages.
b. Ethnicity differences: There are significant differences in mRSS in 
different ethnic groups in dcSSc patients. Japanese patients have lower 
mRSS in U.S. and British cohorts, although there is no study 
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comparing mRSS by the same examiners in different populations. 
These differences could be explained, in part, by different distribution 
of SSc-related serum autoantibodies among ethnic groups; i.e., a higher 
proportion of anti-RNA polymerase III antibody in U.S. and British 
populations, compared with Japanese patients(2).
c. Measurement in limited cutaneous SSc: The mRSS can be assessed 
in lcSSc but in this population it is not a surrogate of disease severity or 
mortality and is generally not sensitive to change (likely due to a 
ceiling effect).
Recommendations for assessing mRSS in clinical trials
A. Phase 3 trial focused on mRSS as the primary outcome measure or a key secondary 
outcome measure
Training is strongly encouraged for standardization of mRSS in any clinical trial of SSc. 
Each assessor who will be performing mRSS in the trial should undergo training. It should 
be highlighted that the same assessor should perform mRSS during the course of the trial. 
We recommend 2 phases for training and this is based on successful training conducted 
during the phase II trial (discussed above in the section ‘Teaching reduces variability of 
mRSS’) and in an ongoing phase III trial.
1. Teaching phase: This should be accomplished by a video demonstration (by an 
expert examining a patient with SSc demonstrating different aspects of skin 
scoring) followed by a live demonstration by an expert on one or more patients 
with SSc.
2. Evaluation Phase: Each trainee examines at least 3 patients with SSc. These 
patients should be different than the training patients, and should preferably 
reflect the inclusion criteria for the proposed trial.
a. The expert should first examine each patient and record his/her mRSS.
b. Trainees should be given the mRSS sheet (Figure 2) and asked to 
examine each patient.
c. Due to the measurement variability in mRSS, we recommend the 
following criteria for certification for the clinical trial.
i. If the trainee is within +/−5 units of the expert’s total score (5 
units is beyond the measurement variability of mRSS(11)) for 
each of the patients, then the trainee has passed the Evaluation 
phase.
ii. If the trainee is within +/−5 units of the experts’ score for 2 of 
3 patients, then the expert should review the discrepancies 
with the trainee and clarify concerns. The trainee should be 
asked to review the mRSS training video and then considered 
to have passed the Evaluation phase.
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iii. If the trainee is within +/−5 units of the experts’ score for 0 or 
1 of 3 patients, then the trainee should repeat the training, 
either on the same day or at another time.
Certification (Figure 5): Due to logistical issues (requirements of patients and costs 
associated with live training), it may be appropriate to accept the certification for other trials 
if the assessor has undergone live training, passed the evaluation phase, and has performed 
the mRSS in an ongoing or recent trial within the last two years. This assumes that the 
assessor is currently performing mRSS in an ongoing trial or has done so in the recent past. 
In addition, regular evaluation should be conducted during the course of a trial to assess 
intra-rater reliability. Otherwise, they are encouraged to undergo recertification.
B. Phase 3 trial where mRSS is a secondary outcome measure or a Phase 2 trial focused 
on mRSS as the primary outcome measure or key secondary outcome measure
We encourage use the aforementioned plan for standardization of the mRSS, but we 
acknowledge the costs associated with training each assessor. In lieu of a formal training 
session, training at an investigator meeting could include a mRSS training video and live 
demonstration on a minimum of 1 SSc patient. Trainees should be provided enough time for 
clarifications. Each trainee should receive a certificate at the end of investigator meeting 
which should be part of the regulatory binder for the trial.
Finally, we recommend discussing the above-outlined guidance with the regulatory agencies 
associated with a specific research trial or drug development program.
C. Other practical aspects in a clinical trial
1. How often to conduct the mRSS: Based on change in mRSS in the published 
clinical trials and extensive experience of the authors in clinical practice, mRSS 
usually does not have clinically meaningful changes (≧4 points) in less than 3 
months. However, there may be pharmacological targets where an earlier effect 
may be seen on mRSS. Therefore, it is reasonable to assess mRSS at least every 
3 months in a clinical situation.
2. Avoid looking at prior mRSS scores and asking patients to judge change in skin 
score since the previous visit to reduce bias.
3. Ask patients to avoid application of moisturizers or cosmetics on day of skin 
scoring.
In conclusion, we have provided recommendations for performance of mRSS and have 
highlighted some areas of uncertainty that can form the agenda for future research.
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Figure 1. 
Three phases of skin involvement in diffuse cutaneous systemic sclerosis.
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Figure 2. 
Modified Rodnan skin score (mRSS) is assessed in 17 different areas. Case report form to 
capture mRSS.
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Figure 3. 
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Figure 3a: Assessment of mRSS using index finger and thumb or two thumbs to measure 
thickness. mRSS =0 where there is no appreciable skin thickness.
Figure 3b: mRSS =1 where there is mild skin thickness.
Figure 3c: mRSS =2 where there is moderate skin thickness.
Figure 3d: mRSS =1 where there is severe skin thickness.
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Figure 4. 
Various techniques to assess mRSS of anatomic areas as shown over the forearm and upper 
arm.
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Figure 5. 
An example of certification to be provided to trainees.
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